ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for monitor Monitoree múltiples cotizaciones en tiempo real de los principales intercambios, como la Bolsa de Valores de Londres, NASDAQ, NYSE, AMEX, Bovespa y más.
47.63
-0.50
(-1.04%)
Cerrado 30 Noviembre 3:00PM
47.63
0.00
(0.00%)
Fuera de horario: 4:00PM

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
47.63
Postura de Compra
47.00
Postura de Venta
48.67
Volume Operado de la Acción
159,226
47.365 Rango del Día 48.23
37.02 Rango de 52 semanas 60.37
Capitalización de Mercado [m]
Precio Anterior
48.13
Precio de Apertura
48.12
Última hora de negociación
Volumen financiero
US$ 7,592,678
Precio Promedio Ponderado
47.6849
Volumen promedio (3 m)
710,614
Acciones en circulación
92,344,268
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-7.25
Beneficio por acción (BPA)
-6.57
turnover
434.25M
Beneficio neto
-606.64M

Acerca de Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Cr... Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
Ultragenyx Pharmaceutical Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RARE. The last closing price for Ultragenyx Pharmaceutical was US$48.13. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of US$ 37.02 to US$ 60.37.

Ultragenyx Pharmaceutical currently has 92,344,268 shares in issue. The market capitalisation of Ultragenyx Pharmaceutical is US$4.44 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -7.25.

RARE Últimas noticias

Ultragenyx to Participate in Investor Conferences in December

NOVATO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

Ultragenyx Presents Positive Update on GTX-102 Angelman Syndrome Program at FAST’s 17th Annual Global Science Summit

Phase 1/2 data show improvements across all domains and confirm that Phase 3 Aspire study is amply powered to establish efficacy of GTX-102 Phase 3 program on track to begin enrollment by...

Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update

Third quarter 2024 total revenue grew 42% versus prior year to $139 million, including Crysvita® revenue of $98 million and Dojolvi® revenue of $21 million Reaffirmed 2024 expected total revenue...

Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update

NOVATO, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products...

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
11.563.3861515085746.0748.6245.4747426047.33739986CS
4-3.51-6.8635119280451.1453.243.0491414148.78157041CS
12-8.91-15.758754863856.5460.3743.0471061452.60358205CS
268.8322.757731958838.860.3737.0279199648.4103041CS
529.1223.682160477838.5160.3737.0277769447.01528709CS
156-31.015-39.436709263178.64588.2231.5269267747.45344956CS
2608.2320.888324873139.4179.64731.5260875460.57641457CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
BSLKBolt Projects Holdings Inc
US$ 0.71
(139.86%)
80.07M
PRZOParaZero Technologies Ltd
US$ 1.24
(94.14%)
202.48M
AIEVThunder Power Holdings Inc
US$ 0.47
(87.25%)
122.71M
PASGPassage Bio Inc
US$ 1.13
(69.52%)
15.43M
EPOWSunrise New Energy Company Ltd
US$ 1.06
(45.21%)
314.9k
APLTApplied Therapeutics Inc
US$ 2.03
(-76.31%)
43.9M
TGLTreasure Global Inc
US$ 0.2944
(-29.08%)
1.85M
PROCProcaps Group SA
US$ 1.51
(-27.75%)
106.08k
SHOTWSafety Shot Inc
US$ 0.104
(-20.00%)
1.43k
MONDMondee Holdings Inc
US$ 0.7102
(-19.59%)
297.63k
PRZOParaZero Technologies Ltd
US$ 1.24
(94.14%)
205.02M
NVDANVIDIA Corporation
US$ 138.25
(2.15%)
141.86M
AIEVThunder Power Holdings Inc
US$ 0.47
(87.25%)
122.71M
RGTIRigetti Computing Inc
US$ 3.05
(27.08%)
116.98M
MARAMARA Holdings Inc
US$ 27.42
(1.86%)
89.54M

RARE Discussion

Ver más
Monksdream Monksdream 3 meses hace
RARE new 52;week high
👍️0
whytestocks whytestocks 4 años hace
News; $RARE Ultragenyx Pharmaceutical Inc (RARE) Q3 2020 Earnings Call Transcript

Image source: The Motley Fool. Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) Q3 2020 Earnings Call Oct 27, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Ultragenyx Pharmaceutical Inc (RARE) Q3 2020 Earnings Call Tr...

Read the whole news RARE - Ultragenyx Pharmaceutical Inc (RARE) Q3 2020 Earnings Call Transcript
👍️0
Erz Erz 4 años hace
Lets go !!!
👍️0
whytestocks whytestocks 5 años hace
News: $RARE Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma

NOVATO, Calif. and NEW YORK, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Royalty Pharma today announced that Ultragenyx has sold to R...

Read the whole news RARE - Ultragenyx Announces Sale of Future European Royalties on Crysvita® (burosumab) for $320 Million to Royalty Pharma
👍️0
whytestocks whytestocks 5 años hace
News: $RARE Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer

NOVATO, Calif., June 17, 2019 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced it has promoted Erik Harris to Executive Vice President...

In case you are interested https://marketwirenews.com/news-releases/ultragenyx-expands-leadership-team-and-promotes-erik-harris-to-chief-commercial-officer-8368310.html
👍️0
Scalp2Trade Scalp2Trade 6 años hace
What does this Miss Primary end points mean for $RARE?

https://finance.yahoo.com/news/ultragenyx-announces-negative-topline-results-120000119.html
👍️0
MinnieM MinnieM 7 años hace
$RARE - FDA approves treatment for rare genetic enzyme disorder
https://www.fda.gov:80/FDAgov/NewsEvents/Newsroom/PressAnnouncements/ucm585308.htm






👍️0
Inoviorulez Inoviorulez 7 años hace
https://seekingalpha.com/article/4101282-ultragenyx-short-opportunity
👍️0
Awl416 Awl416 7 años hace
Uh oh this may get ugly
👍️0
pphm_mike pphm_mike 8 años hace
Congrats to those who got in! Still a long way to run. 100 by EOY.

https://biotechinvesting.info/2016/08/05/ultragenyx/
👍️0
pphm_mike pphm_mike 8 años hace
Here's a more detailed bull case for $RARE

https://biotechinvesting.info/2016/08/05/bull-case-for-ultragenyx-rare/
👍️0
pphm_mike pphm_mike 8 años hace
RARE - Top biotech stock for the money right now: https://biotechinvesting.info/2016/07/22/sold-tgtx-bought-more-rare/

👍️0
stocktrademan stocktrademan 9 años hace
$RARE recent news/filings

bullish 100.28
falling wedge breakout
bullish engulfing candle

## source: finance.yahoo.com

Sat, 05 Dec 2015 18:17:33 GMT ~ Is Ultragenyx Pharmaceutical Inc (RARE) Going to Burn These Hedge Funds?


read full: http://www.insidermonkey.com/blog/is-ultragenyx-pharmaceutical-inc-rare-going-to-burn-these-hedge-funds-397331/
*********************************************************

Thu, 03 Dec 2015 13:30:00 GMT ~ Ultragenyx Announces First Patient Enrolled in Global Phase 3 Study of KRN23 in Adults With X-Linked Hypophosphatemia (XLH)

[GlobeNewswire] - NOVATO, Calif., Dec. 03, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the initiation ...

read full: http://finance.yahoo.com/news/ultragenyx-announces-first-patient-enrolled-133000975.html
*********************************************************

Wed, 02 Dec 2015 21:30:00 GMT ~ Ultragenyx to Present at the Oppenheimer Annual Healthcare Conference

[GlobeNewswire] - NOVATO, Calif., Dec. 02, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil D. Kakkis, ...

read full: http://finance.yahoo.com/news/ultragenyx-present-oppenheimer-annual-healthcare-213000446.html
*********************************************************

Wed, 02 Dec 2015 13:30:00 GMT ~ Ultragenyx Reports Positive Interim 40-Week Data From Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia

[GlobeNewswire] - NOVATO, Calif., Dec. 02, 2015-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim ...

read full: http://finance.yahoo.com/news/ultragenyx-reports-positive-interim-40-133000458.html
*********************************************************

Wed, 18 Nov 2015 18:04:24 GMT ~ ULTRAGENYX PHARMACEUTICAL INC. Financials


read full: http://finance.yahoo.com/q/is?s=rare
*********************************************************

$RARE charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$RARE company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:
$RARE share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$RARE extra dd links

Company name: Ultragenyx Pharmaceutical Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RARE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RARE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RARE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RARE+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RARE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RARE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RARE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RARE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RARE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RARE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RARE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RARE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RARE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RARE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RARE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RARE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RARE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RARE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RARE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RARE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RARE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RARE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RARE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RARE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE



$RARE DD Notes ~ http://www.ddnotesmaker.com/RARE
👍️0
stocktrademan stocktrademan 9 años hace
$RARE recent news/filings

bullish optionable
bull flag breakout

## source: finance.yahoo.com

Tue, 01 Sep 2015 13:29:00 GMT ~ 9:29 am Ultragenyx Pharma announces the presentation of open-label data from five infants with cardiomyopathy due to long-chain fatty acid oxidation disorders treated with triheptanoin


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#rare
*********************************************************

Tue, 01 Sep 2015 13:23:03 GMT ~ Ultragenyx Announces Presentation of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin

[at noodls] - NOVATO, Calif., Sept. 1, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...

read full: http://www.noodls.com/view/CDCD3CE5C6961F414106227884A3B7A5A1BD6EFB
*********************************************************

Tue, 01 Sep 2015 13:00:00 GMT ~ Ultragenyx Announces Presentation of Data From Long-Chain Fatty Acid Oxidation Disorder Patients With Cardiomyopathy Treated With Triheptanoin

[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the presentation ...

read full: http://finance.yahoo.com/news/ultragenyx-announces-presentation-data-long-130000477.html
*********************************************************

Tue, 01 Sep 2015 10:14:52 GMT ~ Coverage initiated on Ultragenyx Pharma by Raymond James


read full: http://finance.yahoo.com/q/ud?s=RARE
*********************************************************

Sat, 22 Aug 2015 17:04:11 GMT ~ ULTRAGENYX PHARMACEUTICAL INC. Financials


read full: http://finance.yahoo.com/q/is?s=rare
*********************************************************

$RARE charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$RARE company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:

Business Description: OTC Markets | Official site of the OTCQX, OTCQB and OTC Pink Marketplaces featuring Free Stock & Bond Quotes, Trade Prices, Chart, Financials and Company News & Information for Investors, Companies and Traders - OTCMarkets.com (window.NREUM||(NREUM={})).loader_config={xpid:"UwMGWVdSGwQIU1RQAgQ="};window.NREUM||(NREUM={}),__nr_require=function(t,e,n){function r(n){if(!e[n]){var o=e[n]={exports:{}};t[n][0].call(o.exports,function(e){var o=t[n][1][e];return r(o?o:e)},o,o.exports)}return e[n].exports}if("function"==typeof __nr_require)return __nr_require;for(var o=0;od;d++)c[d].apply(u,n);return u}function a(t,e){f[t]=s(t).concat(e)}function s(t){return f[t]||[]}function c(){return n(e)}var f={};return{on:a,emit:e,create:c,listeners:s,_events:f}}function r(){return{}}var o="nr@context",i=t("gos");e.exports=n()},{gos:"7eSDFh"}],ee:[function(t,e){e.exports=t("QJf3ax")},{}],3:[function(t){function e(t){try{i.console&&console.log(t)}catch(e){}}var n,r=t("ee"),o=t(1),i={};try{n=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(i.console=!0,-1!==n.indexOf("dev")&&(i.dev=!0),-1!==n.indexOf("nr_dev")&&(i.nrDev=!0))}catch(a){}i.nrDev&&r.on("internal-error",function(t){e(t.stack)}),i.dev&&r.on("fn-err",function(t,n,r){e(r.stack)}),i.dev&&(e("NR AGENT IN DEVELOPMENT MODE"),e("flags: "+o(i,function(t){return t}).join(", ")))},{1:23,ee:"QJf3ax"}],4:[function(t){function e(t,e,n,i,s){try{c?c-=1:r("err",[s||new UncaughtException(t,e,n)])}catch(f){try{r("ierr",[f,(new Date).getTime(),!0])}catch(u){}}return"function"==typeof a?a.apply(this,o(arguments)):!1}function UncaughtException(t,e,n){this.message=t||"Uncaught error with no additional information",this.sourceURL=e,this.line=n}function n(t){r("err",[t,(new Date).getTime()])}var r=t("handle"),o=t(6),i=t("ee"),a=window.onerror,s=!1,c=0;t("loader").features.err=!0,t(5),window.onerror=e;try{throw new Error}catch(f){"stack"in f&&(t(1),t(2),"addEventListener"in window&&t(3),window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)&&t(4),s=!0)}i.on("fn-start",function(){s&&(c+=1)}),i.on("fn-err",function(t,e,r){s&&(this.thrown=!0,n(r))}),i.on("fn-end",function(){s&&!this.thrown&&c>0&&(c-=1)}),i.on("internal-error",function(t){r("ierr",[t,(new Date).getTime(),!0])})},{1:10,2:9,3:7,4:11,5:3,6:24,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],5:[function(t){t("loader").features.ins=!0},{loader:"G9z0Bl"}],6:[function(t){function e(){}if(window.performance&&window.performance.timing&&window.performance.getEntriesByType){var n=t("ee"),r=t("handle"),o=t(1),i=t(2);t("loader").features.stn=!0,t(3),n.on("fn-start",function(t){var e=t[0];e instanceof Event&&(this.bstStart=Date.now())}),n.on("fn-end",function(t,e){var n=t[0];n instanceof Event&&r("bst",[n,e,this.bstStart,Date.now()])}),o.on("fn-start",function(t,e,n){this.bstStart=Date.now(),this.bstType=n}),o.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),this.bstType])}),i.on("fn-start",function(){this.bstStart=Date.now()}),i.on("fn-end",function(t,e){r("bstTimer",[e,this.bstStart,Date.now(),"requestAnimationFrame"])}),n.on("pushState-start",function(){this.time=Date.now(),this.startPath=location.pathname+location.hash}),n.on("pushState-end",function(){r("bstHist",[location.pathname+location.hash,this.startPath,this.time])}),"addEventListener"in window.performance&&(window.performance.addEventListener("webkitresourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.webkitClearResourceTimings()},!1),window.performance.addEventListener("resourcetimingbufferfull",function(){r("bstResource",[window.performance.getEntriesByType("resource")]),window.performance.clearResourceTimings()},!1)),document.addEventListener("scroll",e,!1),document.addEventListener("keypress",e,!1),document.addEventListener("click",e,!1)}},{1:10,2:9,3:8,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],7:[function(t,e){function n(t){i.inPlace(t,["addEventListener","removeEventListener"],"-",r)}function r(t){return t[1]}var o=t("ee").create(),i=t(1)(o),a=t("gos");if(e.exports=o,n(window),"getPrototypeOf"in Object){for(var s=document;s&&!s.hasOwnProperty("addEventListener");)s=Object.getPrototypeOf(s);s&&n(s);for(var c=XMLHttpRequest.prototype;c&&!c.hasOwnProperty("addEventListener");)c=Object.getPrototypeOf(c);c&&n(c)}else XMLHttpRequest.prototype.hasOwnProperty("addEventListener")&&n(XMLHttpRequest.prototype);o.on("addEventListener-start",function(t){if(t[1]){var e=t[1];"function"==typeof e?this.wrapped=t[1]=a(e,"nr@wrapped",function(){return i(e,"fn-",null,e.name||"anonymous")}):"function"==typeof e.handleEvent&&i.inPlace(e,["handleEvent"],"fn-")}}),o.on("removeEventListener-start",function(t){var e=this.wrapped;e&&(t[1]=e)})},{1:25,ee:"QJf3ax",gos:"7eSDFh"}],8:[function(t,e){var n=t("ee").create(),r=t(1)(n);e.exports=n,r.inPlace(window.history,["pushState"],"-")},{1:25,ee:"QJf3ax"}],9:[function(t,e){var n=t("ee").create(),r=t(1)(n);e.exports=n,r.inPlace(window,["requestAnimationFrame","mozRequestAnimationFrame","webkitRequestAnimationFrame","msRequestAnimationFrame"],"raf-"),n.on("raf-start",function(t){t[0]=r(t[0],"fn-")})},{1:25,ee:"QJf3ax"}],10:[function(t,e){function n(t,e,n){t[0]=o(t[0],"fn-",null,n)}var r=t("ee").create(),o=t(1)(r);e.exports=r,o.inPlace(window,["setTimeout","setInterval","setImmediate"],"setTimer-"),r.on("setTimer-start",n)},{1:25,ee:"QJf3ax"}],11:[function(t,e){function n(){f.inPlace(this,p,"fn-")}function r(t,e){f.inPlace(e,["onreadystatechange"],"fn-")}function o(t,e){return e}function i(t,e){for(var n in t)e[n]=t[n];return e}var a=t("ee").create(),s=t(1),c=t(2),f=c(a),u=c(s),d=window.XMLHttpRequest,p=["onload","onerror","onabort","onloadstart","onloadend","onprogress","ontimeout"];e.exports=a,window.XMLHttpRequest=function(t){var e=new d(t);try{a.emit("new-xhr",[],e),u.inPlace(e,["addEventListener","removeEventListener"],"-",o),e.addEventListener("readystatechange",n,!1)}catch(r){try{a.emit("internal-error",[r])}catch(i){}}return e},i(d,XMLHttpRequest),XMLHttpRequest.prototype=d.prototype,f.inPlace(XMLHttpRequest.prototype,["open","send"],"-xhr-",o),a.on("send-xhr-start",r),a.on("open-xhr-start",r)},{1:7,2:25,ee:"QJf3ax"}],12:[function(t){function e(t){var e=this.params,r=this.metrics;if(!this.ended){this.ended=!0;for(var i=0;c>i;i++)t.removeEventListener(s,this.listener,!1);if(!e.aborted){if(r.duration=(new Date).getTime()-this.startTime,4===t.readyState){e.status=t.status;var a=t.responseType,f="arraybuffer"===a||"blob"===a||"json"===a?t.response:t.responseText,u=n(f);if(u&&(r.rxSize=u),this.sameOrigin){var d=t.getResponseHeader("X-NewRelic-App-Data");d&&(e.cat=d.split(", ").pop())}}else e.status=0;r.cbTime=this.cbTime,o("xhr",[e,r,this.startTime])}}}function n(t){if("string"==typeof t&&t.length)return t.length;if("object"!=typeof t)return void 0;if("undefined"!=typeof ArrayBuffer&&t instanceof ArrayBuffer&&t.byteLength)return t.byteLength;if("undefined"!=typeof Blob&&t instanceof Blob&&t.size)return t.size;if("undefined"!=typeof FormData&&t instanceof FormData)return void 0;try{return JSON.stringify(t).length}catch(e){return void 0}}function r(t,e){var n=i(e),r=t.params;r.host=n.hostname+":"+n.port,r.pathname=n.pathname,t.sameOrigin=n.sameOrigin}if(window.XMLHttpRequest&&XMLHttpRequest.prototype&&XMLHttpRequest.prototype.addEventListener&&!/CriOS/.test(navigator.userAgent)){t("loader").features.xhr=!0;var o=t("handle"),i=t(2),a=t("ee"),s=["load","error","abort","timeout"],c=s.length,f=t(1);t(4),t(3),a.on("new-xhr",function(){this.totalCbs=0,this.called=0,this.cbTime=0,this.end=e,this.ended=!1,this.xhrGuids={}}),a.on("open-xhr-start",function(t){this.params={method:t[0]},r(this,t[1]),this.metrics={}}),a.on("open-xhr-end",function(t,e){"loader_config"in NREUM&&"xpid"in NREUM.loader_config&&this.sameOrigin&&e.setRequestHeader("X-NewRelic-ID",NREUM.loader_config.xpid)}),a.on("send-xhr-start",function(t,e){var r=this.metrics,o=t[0],i=this;if(r&&o){var f=n(o);f&&(r.txSize=f)}this.startTime=(new Date).getTime(),this.listener=function(t){try{"abort"===t.type&&(i.params.aborted=!0),("load"!==t.type||i.called===i.totalCbs&&(i.onloadCalled||"function"!=typeof e.onload))&&i.end(e)}catch(n){try{a.emit("internal-error",[n])}catch(r){}}};for(var u=0;c>u;u++)e.addEventListener(s,this.listener,!1)}),a.on("xhr-cb-time",function(t,e,n){this.cbTime+=t,e?this.onloadCalled=!0:this.called+=1,this.called!==this.totalCbs||!this.onloadCalled&&"function"==typeof n.onload||this.end(n)}),a.on("xhr-load-added",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&!this.xhrGuids[n]&&(this.xhrGuids[n]=!0,this.totalCbs+=1)}),a.on("xhr-load-removed",function(t,e){var n=""+f(t)+!!e;this.xhrGuids&&this.xhrGuids[n]&&(delete this.xhrGuids[n],this.totalCbs-=1)}),a.on("addEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&a.emit("xhr-load-added",[t[1],t[2]],e)}),a.on("removeEventListener-end",function(t,e){e instanceof XMLHttpRequest&&"load"===t[0]&&a.emit("xhr-load-removed",[t[1],t[2]],e)}),a.on("fn-start",function(t,e,n){e instanceof XMLHttpRequest&&("onload"===n&&(this.onload=!0),("load"===(t[0]&&t[0].type)||this.onload)&&(this.xhrCbStart=(new Date).getTime()))}),a.on("fn-end",function(t,e){this.xhrCbStart&&a.emit("xhr-cb-time",[(new Date).getTime()-this.xhrCbStart,this.onload,e],e)})}},{1:"XL7HBI",2:13,3:11,4:7,ee:"QJf3ax",handle:"D5DuLP",loader:"G9z0Bl"}],13:[function(t,e){e.exports=function(t){var e=document.createElement("a"),n=window.location,r={};e.href=t,r.port=e.port;var o=e.href.split("://");return!r.port&&o[1]&&(r.port=o[1].split("/")[0].split("@").pop().split(":")[1]),r.port&&"0"!==r.port||(r.port="https"===o[0]?"443":"80"),r.hostname=e.hostname||n.hostname,r.pathname=e.pathname,r.protocol=o[0],"/"!==r.pathname.charAt(0)&&(r.pathname="/"+r.pathname),r.sameOrigin=!e.hostname||e.hostname===document.domain&&e.port===n.port&&e.protocol===n.protocol,r}},{}],14:[function(t,e){function n(t){return function(){r(t,[(new Date).getTime()].concat(i(arguments)))}}var r=t("handle"),o=t(1),i=t(2);"undefined"==typeof window.newrelic&&(newrelic=window.NREUM);var a=["setPageViewName","addPageAction","setCustomAttribute","finished","addToTrace","inlineHit","noticeError"];o(a,function(t,e){window.NREUM[e]=n("api-"+e)}),e.exports=window.NREUM},{1:23,2:24,handle:"D5DuLP"}],gos:[function(t,e){e.exports=t("7eSDFh")},{}],"7eSDFh":[function(t,e){function n(t,e,n){if(r.call(t,e))return t[e];var o=n();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(t,e,{value:o,writable:!0,enumerable:!1}),o}catch(i){}return t[e]=o,o}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],D5DuLP:[function(t,e){function n(t,e,n){return r.listeners(t).length?r.emit(t,e,n):void(r.q&&(r.q[t]||(r.q[t]=[]),r.q[t].push(e)))}var r=t("ee").create();e.exports=n,n.ee=r,r.q={}},{ee:"QJf3ax"}],handle:[function(t,e){e.exports=t("D5DuLP")},{}],XL7HBI:[function(t,e){function n(t){var e=typeof t;return!t||"object"!==e&&"function"!==e?-1:t===window?0:i(t,o,function(){return r++})}var r=1,o="nr@id",i=t("gos");e.exports=n},{gos:"7eSDFh"}],id:[function(t,e){e.exports=t("XL7HBI")},{}],G9z0Bl:[function(t,e){function n(){var t=p.info=NREUM.info,e=f.getElementsByTagName("script")[0];if(t&&t.licenseKey&&t.applicationID&&e){s(d,function(e,n){e in t||(t[e]=n)});var n="https"===u.split(":")[0]||t.sslForHttp;p.proto=n?"https://":"http://",a("mark",["onload",i()]);var r=f.createElement("script");r.src=p.proto+t.agent,e.parentNode.insertBefore(r,e)}}function r(){"complete"===f.readyState&&o()}function o(){a("mark",["domContent",i()])}function i(){return(new Date).getTime()}var a=t("handle"),s=t(1),c=window,f=c.document;t(2);var u=(""+location).split("?")[0],d={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",agent:"js-agent.newrelic.com/nr-686.min.js"},p=e.exports={offset:i(),origin:u,features:{}};f.addEventListener?(f.addEventListener("DOMContentLoaded",o,!1),c.addEventListener("load",n,!1)):(f.attachEvent("onreadystatechange",r),c.attachEvent("onload",n)),a("mark",["firstbyte",i()])},{1:23,2:14,handle:"D5DuLP"}],loader:[function(t,e){e.exports=t("G9z0Bl")},{}],23:[function(t,e){function n(t,e){var n=[],o="",i=0;for(o in t)r.call(t,o)&&(n=e(o,t[o]),i+=1);return n}var r=Object.prototype.hasOwnProperty;e.exports=n},{}],24:[function(t,e){function n(t,e,n){e||(e=0),"undefined"==typeof n&&(n=t?t.length:0);for(var r=-1,o=n-e||0,i=Array(0>o?0:o);++r

$RARE share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$RARE extra dd links

Company name: Ultragenyx Pharmaceutical Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RARE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RARE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RARE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RARE+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RARE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RARE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RARE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RARE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RARE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RARE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RARE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RARE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RARE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RARE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RARE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RARE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RARE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RARE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RARE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RARE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RARE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RARE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RARE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RARE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE



$RARE DD Notes ~ http://www.ddnotesmaker.com/RARE
👍️0
stocktrademan stocktrademan 9 años hace
$RARE recent news/filings

bullish
higher highs, higher lows uptrend
unusually strong green CMF indicator, people are definitely buying
climbing acc/dist line
good volume

pharmaceutical index gapping up strong bullish, stocks follow the index



## source: finance.yahoo.com

Fri, 10 Jul 2015 16:42:45 GMT ~ Story Stocks from Briefing.com

[Briefing.com] - Story Stocks from Briefing.com

read full: http://finance.yahoo.com/news/story-stocks-briefing-com-112019114.html
*********************************************************

Thu, 09 Jul 2015 13:09:13 GMT ~ Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia

[at noodls] - NOVATO, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...

read full: http://www.noodls.com/view/889E805479FA8AE62C572F0F3A8432243E350652
*********************************************************

Thu, 09 Jul 2015 13:01:00 GMT ~ 9:01 am Ultragenyx Pharma announced positive interim data in the ongoing pediatric Phase 2 study for recombinant human monoclonal antibody KRN23


read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#rare
*********************************************************

Thu, 09 Jul 2015 13:00:00 GMT ~ Ultragenyx Releases Positive Interim 40-Week Bone Treatment Data From Ongoing Pediatric Phase 2 Study of KRN23 in X-Linked Hypophosphatemia

[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced positive interim ...

read full: http://finance.yahoo.com/news/ultragenyx-releases-positive-interim-40-130000004.html
*********************************************************

Thu, 09 Jul 2015 10:58:16 GMT ~ Coverage initiated on Ultragenyx Pharma by JMP Securities


read full: http://finance.yahoo.com/q/ud?s=RARE
*********************************************************

$RARE charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$RARE company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:


$RARE share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$RARE extra dd links

Company name: Ultragenyx Pharmaceutical Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RARE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RARE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RARE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RARE+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RARE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RARE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RARE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RARE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RARE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RARE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RARE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RARE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RARE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RARE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RARE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RARE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RARE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RARE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RARE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RARE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RARE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RARE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RARE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RARE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE



$RARE DD Notes ~ http://www.ddnotesmaker.com/RARE
👍️0
stocktrademan stocktrademan 9 años hace
$RARE recent news/filings

bullish

## source: finance.yahoo.com

Mon, 08 Jun 2015 13:17:02 GMT ~ Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

[at noodls] - NOVATO, Calif., June 8, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...

read full: http://www.noodls.com/view/6C3658995B817A651D2EC2AE11B355A918994EF6
*********************************************************

Mon, 08 Jun 2015 13:00:00 GMT ~ Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has completed patient enrollment ...

read full: http://finance.yahoo.com/news/ultragenyx-announces-completion-enrollment-phase-130000501.html
*********************************************************

Thu, 04 Jun 2015 13:31:11 GMT ~ Ultragenyx Appoints Dennis Huang as Chief Technical Operations Officer and Senior Vice President

[at noodls] - NOVATO, Calif., June 4, 2015 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...

read full: http://www.noodls.com/view/F3860C2675B8ADEE791EB0BC3C0FE3CA94026752
*********************************************************

Thu, 04 Jun 2015 13:00:00 GMT ~ Ultragenyx Appoints Dennis Huang as Chief Technical Operations Officer and Senior Vice President

[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced it has appointed Dennis Huang ...

read full: http://finance.yahoo.com/news/ultragenyx-appoints-dennis-huang-chief-130000146.html
*********************************************************

Wed, 03 Jun 2015 19:00:07 GMT ~ Ultragenyx KRN23 Positive in Children, to be Studied in Adults - Analyst Blog


read full: http://finance.yahoo.com/news/ultragenyx-krn23-positive-children-studied-190007809.html
*********************************************************

$RARE charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$RARE company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:


$RARE share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$RARE extra dd links

Company name: Ultragenyx Pharmaceutical Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/RARE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/RARE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=RARE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=RARE+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/RARE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/RARE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/RARE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/RARE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/RARE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/RARE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/RARE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/RARE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/RARE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/RARE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/RARE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/RARE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=RARE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=RARE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=RARE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=RARE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/RARE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/RARE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/RARE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/RARE/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/RARE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/RARE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/RARE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE



$RARE DD Notes ~ http://www.ddnotesmaker.com/RARE
👍️0
DITRLI DITRLI 10 años hace
$RARE Top performing IPO in 2014
http://ditrli.com/smart-investing-2014-ipo-winners/
👍️0
maytepper maytepper 10 años hace
$RARE Cowen Sees Ultragenyx Shares Outperforming Following Phase 1/2 Data http://www.smarteranalyst.com/2014/09/16/cowen-sees-ultragenyx-shares-outperforming-following-phase-12-data/
👍️0
stocktrademan stocktrademan 10 años hace
Ultragenyx Pharmaceutical Inc. [$RARE] due diligence

bullish 120% gain or more on margin

perhaps an inverted head and shoulders pattern forming
http://stockcharts.com/school/doku.php?st=head+and+shoulders&id=chart_school:chart_analysis:chart_patterns:head_and_shoulders_bottom_reversal

hidden bullish macd divergence since June
http://www.tradingsetupsreview.com/macd-hidden-divergence-trading-strategy/



$RARE

DD Notes ~ http://www.ddnotesmaker.com/RARE

##### recent news/filings ~ source: finance.yahoo.com

Wed, 09 Jul 2014 10:52:19 GMT ~ Ultragenyx Pharmaceutical Slumps: RARE Plunges 11.7% in Session
read full: http://finance.yahoo.com/news/ultragenyx-pharmaceutical-slumps-rare-plunges-105219468.html
*********************************************************

Wed, 09 Jul 2014 10:16:06 GMT ~ Ultragenyx Announces Pricing of Public Offering of Common Stock
[at noodls] - NOVATO, Calif., July 9, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
read full: http://www.noodls.com/view/9FFE8CBF956DB796051313BCC01A85BC64120648
*********************************************************

Wed, 09 Jul 2014 05:00:00 GMT ~ Ultragenyx Announces Pricing of Public Offering of Common Stock
[GlobeNewswire] - NOVATO, Calif. -- Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced the pricing of its underwritten ...
read full: http://finance.yahoo.com/news/ultragenyx-announces-pricing-public-offering-050000787.html
*********************************************************

Tue, 08 Jul 2014 18:10:38 GMT ~ Why Ultragenyx Pharmaceutical Inc. Stock Slumped
read full: http://www.fool.com/investing/general/2014/07/08/why-ultragenyx-pharmaceutical-inc-stock-slumped.aspx?source=eogyholnk0000001
*********************************************************

Mon, 07 Jul 2014 20:41:47 GMT ~ Ultragenyx Announces Proposed Public Offering of Common Stock
[at noodls] - NOVATO, Calif., July 7, 2014 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (Nasdaq:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, ...
read full: http://www.noodls.com/view/C0A7B5AFC8509CEBEF230D67C95F9CEC8E0806B3
*********************************************************

##### chart ~ source: stockcharts.com



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/RARE/company-info
Ticker: $RARE
OTC Market Place: Not Available
CIK code: not found
Company name: Ultragenyx Pharmaceutical Inc.
Incorporated In:

##### extra dd links

Latest filings: http://www.otcmarkets.com/stock/RARE/filings
Latest financials: http://www.otcmarkets.com/stock/RARE/financials
Latest news: http://www.otcmarkets.com/stock/RARE/news - http://finance.yahoo.com/q/h?s=RARE+Headlines

Major holdings: http://data.cnbc.com/quotes/RARE/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=RARE+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/RARE.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=RARE

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=RARE&search=search

DTCC: http://search2.dtcc.com/?q=Ultragenyx+Pharmaceutical+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Ultragenyx+Pharmaceutical+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Ultragenyx+Pharmaceutical+Inc.&x=0&y=0

Short Sales: http://www.otcmarkets.com/stock/RARE/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/RARE/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/RARE/research
Historical Prices: http://finance.yahoo.com/q/hp?s=RARE+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=RARE+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=RARE+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=RARE+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=RARE+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=RARE+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=RARE
Balance Sheet: http://finance.yahoo.com/q/bs?s=RARE
Cash Flow: http://finance.yahoo.com/q/cf?s=RARE+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/RARE
Bloomberg: http://www.bloomberg.com/quote/RARE:US
Morningstar: http://quotes.morningstar.com/stock/s?t=RARE
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=RARE
Barchart: http://www.barchart.com/quotes/stocks/RARE
OTC Short Report: http://otcshortreport.com/index.php?index=RARE
Investopedia: http://www.investopedia.com/markets/stocks/RARE/?wa=0

http://www.pennystocktweets.com/stocks/profile/RARE

##### last known share structure ~ source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

##### business description ~ source: otcmarkets.com



DD Notes ~ http://www.ddnotesmaker.com/RARE
a11k
👍️0
SchlumpyStock-Picker SchlumpyStock-Picker 11 años hace
Presentation is at 4:00 PM. Today.

4:00
Joyce E Fox
Steven and Alexandra Cohen Children?s Medical Center
New York, NY, United States
Recombinant Human beta-glucuronidase enzyme replacement therapy for mucopolysaccharidosis type VII: report of the first patient treated.

Maybe a surge in PPS tomorrow when attendees invest in RARE
👍️0
SchlumpyStock-Picker SchlumpyStock-Picker 11 años hace
Low Float with plenty of up side.
👍️0
RealGenius RealGenius 11 años hace
Just nuts. Slated to issue at $17 per share. Instead issues at $21, then doubles?
👍️0
Mtrader16 Mtrader16 11 años hace
Nice moves here!
👍️0

Su Consulta Reciente

Delayed Upgrade Clock